- Mortgage Rates Fall, With 30-Year Fixed at 4.83%
- Leading Indicators, Philly Fed Show Slow Growth
- Geithner Trades Barbs With Congressman
- Geithner: Fast Action Needed On Financial Overhaul
- Administration Promises Stimulus Job Count Changes
- Jobless Claims Trend Shows Labor Market in Slow Heal
- Slideshow: The High-End Art of the Comic Strip
- Post-Mortems Reveal Obvious Risk at Banks
- Employers Start to Restore 401(k) Matches: Survey
- Gold's 'Money' Value is $4,000 to $11,000: Market Strategist
- Dorn: Trading Secrets and Serendipity
- Schork Oil Outlook: Falling Demand and Falling Production—The Race is On
- Busch: Ron Paul Fed Day
- Coffee, Tea or My Ad?
- Commercial Real Estate Bottom Near: Market Pro
- Despite Government Aid, Foreclosure Crisis is Not Improving
- Betting Against Equities is a 'Fool's Game': Strategist
- Volvo Talks Show New Day Dawning for China
- JetBlue launches one-day sale
- Electronic bingo operations in Alabama shut down
- Wyo. committee declines to endorse wind tax bills
- Verizon Wireless lays off former Alltel workers
- Ross Stores 3Q profit rises on lower inventories
- Idaho schools face cuts, agencies face elimination
- NC state budget has $600M-plus for any shortfall
- Arizona senators vote to start over on loan issue
- Some of Neb. lawmakers' funds shielded from cuts
Text Size 
NEW YORK - Medical device maker Boston Scientific Corp. said Friday it will pay $296 million to settle a Department of Justice investigation into the company's Guidant unit.
The company also said it will take a charge of $294 million in the third quarter.
The investigation involved product advisories issued by Guidant in 2005, a year before Boston Scientific paid $27 billion for the heart device maker. Throughout 2007, Boston Scientific agreed to various settlements over heart patients' legal claims that Guidant knowingly sold defibrillators with potentially life-threatening defects over a three-year period.
The company was also criticized for taking too long to notify doctors, patients and regulators about potential problems.
Under the current deal, Guidant will plead to two misdemeanor charges related to failure to include information in reports to the U.S. Food and Drug Administration.
Natick, Mass. Boston Scientific updated its third-quarter profit results to reflect the charge. It is now reporting a third-quarter loss of $94 million, or 6 cents per share, instead of a $250 million, or 13 cents per share profit.
Adjusted profit, which excludes the charge, still stands at 19 cents per share.
The company now expects a charge of 20 cents per share to be included in full-year profit results. It now expects profit between 23 cents and 28 cents per share in 2009, while analysts surveyed by Thomson Reuters had forecast profit of 50 cents per share.
Boston Scientific shares rose 10 cents to $8.15 in morning trading.
Print
Email
- Alternative energy's hot spot is making a comeback after some dark days in the past year.
- Should older investors purge their investment portfolios of stocks altogether or risk running out of money?
- With advertising proliferating seemingly everywhere, what can an advertiser to do to get your attention?
- Can the reviled 2001 Pontiac Aztek lead GM into the future? The Big Money looks at the possibilities.
- If you've been dreaming about heading down to Miami in February for the Super Bowl, you just might want to check the airfare.
- What's behind the recent and sudden disappearance of Eggo waffles from supermarket shelves?
Data is a real-time snapshot *Data is delayed at least 15 minutes